Pilot study to examine the efficacy of terlipressin in the treatment of hepatorenal syndrome.

A non-blinded randomised control study to examine the efficacy of terlipressin compared to standard care in improving renal function in patients with hepatorenal syndrome.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000562673

Enrollment

Registered

2005-09-30

Start date

2004-02-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Standard care + terlipressin for hepatorenal syndrome Duration of intervention is 5 days.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Cirrhotic patients admitted with hepatorenal syndrome (serum creatinine >0.15 with urine sodium <20 mmol).

Exclusion criteria

Use of other vasoactive drugs, pregnancy, age <18 years, known severe coronary artery disease, AMI within previous 6 months, known intestinal iscchaemia, known severe cerebrovascular disease, CVA within previous 6 months and uncontrolled hypertension.

Outcome results